No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
362 |
4. Check minimum number of eventsNone |
362 |
5. Include endpointsNone |
362 |
6. Filter based on genotype QC (FinnGen only) |
330 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E34
- Name in latin
- Syndroma carcinoides
Similar endpoints
↥List of similar endpoints to
Carcinoid syndrome
based on the number of shared cases.
Similar with more cases:
- Other endocrine disorders
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1609 | 854 | 744 |
| Only index persons | 1230 | 666 | 564 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 64.12 | 63.82 | 64.35 |
| Only index persons | 62.75 | 62.30 | 63.27 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 330 | 158 | 172 |
| Unadjusted period prevalence (%) | 0.07 | 0.06 | 0.08 |
| Median age at first event (years) | 62.56 | 60.74 | 64.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 340
- Matched controls
- 3400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E34.0
ICD-10 Finland
Carcinoid syndrome
+∞
307.7
319
*
130
Kela drug reimbursment
Malignant tumour
31.4
243.0
226
202
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
36.3
167.4
113
46
JFB00
NOMESCO Finland
Partial resection of small intestine
81.2
166.1
90
15
H01CB02
ATC
octreotide; parenteral
1144.9
152.8
138
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
557.9
145.9
135
*
H01CB03
ATC
lanreotide; parenteral
+∞
135.8
121
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
21.8
128.8
107
70
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
26.7
126.4
94
48
JN4CD
NOMESCO Finland
Very extensive body CT
20.6
112.0
94
62
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
64.7
105.4
59
11
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
1347.5
105.1
97
*
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
+∞
101.2
92
*
JN4BD
NOMESCO Finland
Extensive body CT
9.9
95.0
149
248
JN3BD
NOMESCO Finland
Extensive abdominal CT
10.1
90.3
133
204
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
26.2
81.7
59
27
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
+∞
72.5
67
*
JN4AD
NOMESCO Finland
Body CT examination
7.5
71.5
141
292
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
17.9
70.8
61
41
WX302
NOMESCO Finland
Thoracal epidural anesthesy
11.8
68.1
78
84
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
24.3
67.6
50
24
L01AX03
ATC
temozolomide; systemic
116.6
62.4
66
7
C17.2
ICD-10 Finland
Malignant neoplasm: Ileum
707.8
61.8
59
*
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
112.3
60.3
64
7
JFB30
NOMESCO Finland
Right hemicolectomy
25.8
59.9
43
19
8240/3-C17.9
ICD-O-3
Neuroendocrine tumor, NOS, of small intestine, NOS
+∞
58.0
54
*
D77
ICPC
Malignant digestive neopl other/NOS
103.8
56.0
60
7
L01BC06
ATC
capecitabine; oral
10.1
52.9
66
79
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
7.9
49.7
78
123
A03FA01
ATC
metoclopramide; systemic, rectal
5.0
47.6
165
540
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.6
47.4
92
181
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
99.7
47.3
51
6
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
12.8
44.9
46
41
WVA30, ,
SPAT
7.3
44.4
74
124
A04AA02
ATC
granisetron; systemic, transdermal
7.1
43.2
75
131
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
16.7
41.4
36
24
JKA20
NOMESCO Finland
Cholecystectomy
11.6
40.4
44
43
302
Kela drug reimbursment
Interferon alfa
+∞
38.3
36
*
A79
ICPC
Malignancy NOS
13.3
37.4
37
31
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
11.8
37.3
40
38
T73
ICPC
Neoplasm endocrine other/unspecified
+∞
37.2
35
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
15.0
37.0
34
25
C10AC01
ATC
colestyramine; oral
10.4
34.2
40
43
Z51.5
ICD-10 Finland
Palliative care
5.0
33.3
88
224
C17.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of small intestine
+∞
32.8
31
*
JN7SN
NOMESCO Finland
Somatostatin receptor SPECT
+∞
30.7
29
*
L03AB05
ATC
interferon alfa-2b; parenteral
75.2
30.5
34
5
JN4SR
NOMESCO Finland
Very extensive PET-CT of receptors in whole body
330.2
30.3
30
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.9
30.0
60
119
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
8.6
29.5
40
52
JN3AD
NOMESCO Finland
Abdominal CT examination
4.2
28.5
97
298
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.4
27.8
180
840
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.1
27.1
93
286
JN7AN
NOMESCO Finland
Somatostatin receptor isotope imaging
+∞
26.4
25
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
5.8
25.9
52
103
C25.4
ICD-10 Finland
Malignant neoplasm: Endocrine pancreas
268.9
25.0
25
*
N02AA05
ATC
oxycodone; systemic
3.4
24.5
121
472
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
24.4
141
604
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
24.3
23
*
8249/3-C17.9
ICD-O-3
Neuroendocrine tumor, grade 2 of small intestine, NOS
+∞
24.3
23
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
23.9
161
753
8240/3-C17.2
ICD-O-3
Neuroendocrine tumor, NOS, of ileum
123.0
21.9
23
*
JAH00
NOMESCO Finland
Laparotomy
6.7
21.1
35
57
WZC00
NOMESCO Finland
Treatment plan or consultation
2.9
20.5
173
897
XX9AD
NOMESCO Finland
Complementary CT
+∞
20.0
19
*
UJF32
NOMESCO Finland
Coloscopy
2.9
19.4
142
679
A50
ICPC
General and Unspecified, Medication/prescr/renewal
6.3
18.3
32
55
D76
ICPC
Malignant neoplasm pancreas
33.5
17.3
22
7
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
13.7
17.0
29
23
8246/3-C17.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of small intestine, NOS
+∞
16.8
16
*
C18.99
ICD-10 Finland
Malignant tumor in unspecified location in the colon other or unspecified histology
178.4
16.6
17
*
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
31.8
16.3
21
7
C17.0
ICD-10 Finland
Malignant neoplasm: Duodenum
167.4
15.6
16
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.6
15.5
134
683
B03BA03
ATC
hydroxocobalamin; parenteral
4.3
15.4
42
107
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.5
15.3
188
1125
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.3
15.3
32
65
JN4DD
NOMESCO Finland
Scout CT scan of torso
47.3
15.2
18
*
SPAT1254
SPAT
Administration of medicine
3.1
15.1
77
297
158
Kela drug reimbursment
Everolimus
83.8
14.7
16
*
C18.09
ICD-10 Finland
Malignant tumor of caecum other or unspecified histology
83.8
14.7
16
*
C18.19
ICD-10 Finland
Malignant tumor in appendix other or unspecified histology
+∞
14.7
14
*
340
Kela drug reimbursment
Everolimus
+∞
14.7
14
*
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
37.9
14.6
18
5
B81
ICPC
Anaemia vit B12/folate deficiency
5.2
14.6
31
64
ZXD05
NOMESCO Finland
Urgent procedure
2.5
14.5
130
669
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.0
14.5
45
126
XX2RW, ,
NOMESCO Finland
20.3
14.4
21
11
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
14.2
216
1408
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
15.6
13.8
22
15
ZXE10
NOMESCO Finland
More than one and less than three hours
2.4
13.7
158
906
JAH01
NOMESCO Finland
Laparoscopy
5.4
13.6
28
56
C17.1
ICD-10 Finland
Malignant neoplasm: Jejunum
145.6
13.5
14
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
4.7
13.4
32
73
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
15.9
13.3
21
14
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
41.9
13.3
16
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
13.1
107
524
C18.90
ICD-10 Finland
Malignant tumor in unspecified location in the colon without histology
72.6
12.7
14
*
JLC10
NOMESCO Finland
Distal pancreatectomy
72.6
12.7
14
*
2592A
ICD-9 Finland
Other endocrine disorders, Carcinoid syndrome
+∞
12.6
12
*
8249/3-C17.2
ICD-O-3
Neuroendocrine tumor, grade 2 of ileum
+∞
12.6
12
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
10.2
12.4
24
25
A55
ICPC
General and Unspecified, Local injection/infiltration
16.7
12.3
19
12
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.3
12.2
33
83
JFB20
NOMESCO Finland
Ileocaecal resection
22.3
12.1
17
8
R4190
NOMESCO Finland
Nutritional therapy
5.1
12.1
26
54
C25.2
ICD-10 Finland
Malignant neoplasm: Tail of pancreas
48.5
12.0
14
*
L01CB01
ATC
etoposide; systemic
19.8
11.7
17
9
-50
ICPC
Medication/prescr/renewal
4.3
11.7
31
77
A04AA01
ATC
ondansetron; systemic, rectal
3.3
11.5
48
163
E340, C179,
ICD-10 Finland
+∞
11.5
11
*
B01AB04
ATC
dalteparin; parenteral
4.4
11.3
29
70
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
13.3
11.3
19
15
TPH07
NOMESCO Finland
Cathetrisation of artery
2.8
11.2
64
261
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
5.2
10.9
23
47
B01AB10
ATC
tinzaparin; parenteral
2.8
10.7
60
242
R11
ICD-10 Finland
Nausea and vomiting
3.1
10.6
48
171
107
Kela drug reimbursment
Pernicious anaemia
8.6
10.5
22
27
8249/3-C25.9
ICD-O-3
Neuroendocrine tumor, grade 2 of pancreas, NOS
+∞
10.5
10
*
JN5SR
NOMESCO Finland
Very extensive PET-CT of receptors in upper body
+∞
10.5
10
*
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
4.7
10.4
25
57
WVA20, ,
SPAT
4.7
10.4
25
57
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
33.7
10.4
13
*
ZXE20
NOMESCO Finland
More than three and less than five hours
2.6
10.3
70
311
UJF92
NOMESCO Finland
Capsular endoscopy
8.9
10.2
21
25
J01MA12
ATC
levofloxacin; systemic
2.4
10.1
89
444
C03CA01
ATC
furosemide; systemic
2.1
10.1
142
857
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
41.4
10.0
12
*
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
41.4
10.0
12
*
JF1BD
NOMESCO Finland
Very extensive small bowel CT
17.4
10.0
15
9
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.3
9.9
91
462
S50
ICPC
Skin, Medication/prescr/renewal
26.9
9.9
13
5
B01AB05
ATC
enoxaparin; parenteral
2.1
9.8
139
840
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
5.4
9.5
19
37
8240/3-C34.9
ICD-O-3
Neuroendocrine tumor, NOS, of lung, NOS
102.8
9.5
10
*
D13.7
ICD-10 Finland
Benign neoplasm: Endocrine pancreas
102.8
9.5
10
*
8240/3-C18.2
ICD-O-3
Neuroendocrine tumor, NOS, of ascending colon
102.8
9.5
10
*
JJB10
NOMESCO Finland
Atypcal resection of liver
22.4
9.4
13
6
L01EG02
ATC
everolimus; oral
+∞
9.4
9
*
D13.1
ICD-10 Finland
Benign neoplasm: Stomach
8.1
9.3
20
26
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
19.2
9.0
13
7
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
9.0
8.9
18
21
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.9
8.8
26
70
A02BC05
ATC
esomeprazole; systemic
2.0
8.6
160
1054
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
10.4
8.6
16
16
UJF30
NOMESCO Finland
Ileoscopy through colon
2.7
8.5
51
212
JJA20
NOMESCO Finland
Open biopsy of liver
92.3
8.5
9
*
H02AB02
ATC
dexamethasone; systemic
2.5
8.4
58
258
C80.98
ICD-10 Finland
Malignant tumor without specified localization other specified histology
+∞
8.4
8
*
8249/3-C80.9
ICD-O-3
Neuroendocrine tumor, grade 2 of unknown primary site
+∞
8.4
8
*
8240/3-C16.9
ICD-O-3
Neuroendocrine tumor, NOS, of stomach, NOS
+∞
8.4
8
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
8.4
8
*
8240/3-C20.9
ICD-O-3
Neuroendocrine tumor, NOS, of rectum, NOS
+∞
8.4
8
*
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
2.6
7.9
50
213
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
2.7
7.7
42
166
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
18.9
7.6
11
6
197
Kela drug reimbursment
Sunitinib
25.7
7.6
10
*
C18.91
ICD-10 Finland
Malignant tumor of unspecified location in colon invasive carcinoma
81.8
7.4
8
*
JLC11
NOMESCO Finland
Laparoscopic distal pancreatectomy
81.8
7.4
8
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
81.8
7.4
8
*
JLC30
NOMESCO Finland
Pancreatoduodenectomy
13.8
7.4
12
9
Z51.88
ICD-10 Finland
Other specified medical care
7.1
7.4
17
25
I36.1
ICD-10 Finland
Nonrheumatic tricuspid (valve) insufficiency
6.5
7.3
18
29
8246/3-C80.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of unknown primary site
+∞
7.3
7
*
1CB02, ,
NOMESCO Finland
+∞
7.3
7
*
8240/3-C25.9
ICD-O-3
Neuroendocrine tumor, NOS, of pancreas, NOS
+∞
7.3
7
*
1522B
ICD-9 Finland
Malignant neoplasm of small intestine, including duodenum, Ileum[NEOPLASMA MALIGNUM ILEI,ALIA DEFINITA SEU NUD]
+∞
7.3
7
*
D37.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Colon
7.6
7.3
16
22
E21.0
ICD-10 Finland
Primary hyperparathyroidism
30.7
7.2
9
*
K80.0
ICD-10 Finland
Calculus of gallbladder with acute cholecystitis
3.8
7.1
22
61
D75
ICPC
Malignant neoplasm colon/rectum
10.3
7.1
13
13
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
7.0
89
508
XX3DW
NOMESCO Finland
Time consuming IT work
2.3
6.9
57
274
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.7
6.8
38
152
L01XE10
ATC
[U] everolimus
40.9
6.8
8
*
S55
ICPC
Skin, Local injection/infiltration
40.9
6.8
8
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
9.0
6.6
13
15
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
10.3
6.6
12
12
WZC30
NOMESCO Finland
Teaching
2.1
6.6
75
410
N02AX02
ATC
tramadol; systemic, rectal
1.8
6.5
163
1154
D74
ICPC
Malignant neoplasm stomach
71.1
6.4
7
*
D50
ICPC
Digestive, Medication/prescr/renewal
71.1
6.4
7
*
T50
ICPC
Metabolic, Medication/prescr/renewal
71.1
6.4
7
*
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
14.7
6.4
10
7
ZX120
NOMESCO Finland
Intravenous
2.4
6.4
44
195
JAP00
NOMESCO Finland
Freeing of adhesions in the peritoneal cavity
9.5
6.3
12
13
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
5.2
6.3
18
36
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
+∞
6.3
6
*
8240/3-C80.9
ICD-O-3
Neuroendocrine tumor, NOS, of unknown primary site
+∞
6.3
6
*
8246/3-C25.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of pancreas, NOS
+∞
6.3
6
*
JJB60
NOMESCO Finland
Other excsion of three or more segments of liver
+∞
6.3
6
*
SPAT1262
SPAT
Handing over of treatment supplies
2.0
6.2
74
412
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
10.3
6.1
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
241
14
588.76
307.65
11.4
3.4
427.14
66.07
nmol/l
7.20
241
14
261
32
347.72
307.65
12.2
2.9
21.12
8.59
nmol/l
1.02
256
32
65
98
7.96
42.84
1.5
1.4
220.09
294.91
ug/g
1.82
48
60
120
334
5.01
41.54
2.5
2.4
0.22
0.21
g/l
0.55
113
313
125
398
4.39
35.79
3.6
4.7
11.87
41.20
ug/l
0.80
98
341
247
1466
3.50
24.44
10.2
5.3
35.47
35.34
g/l
0.16
240
1374
208
1139
3.13
23.16
9.0
3.7
2.34
2.35
mmol/l
0.44
201
1022
205
1141
3.01
21.66
5.4
3.4
866.14
1304.66
ng/l
1.91
188
993
269
1770
3.49
20.66
20.6
10.4
3.57
4.17
e9/l
5.08
249
1537
77
255
3.61
19.70
4.1
3.1
97.59
204.81
ng/l
3.63
69
230
77
265
3.46
18.49
5.7
3.6
1.22
1.22
mmol/l
0.20
77
223
255
1686
3.05
18.19
9.3
7.4
1.21
1.21
mmol/l
0.01
195
1453
238
1526
2.87
17.82
7.9
6.7
1.22
1.21
mmol/l
1.16
225
1390
109
491
2.80
16.21
2.5
2.4
21.17
22.35
%
0.34
102
465
112
522
2.71
15.49
2.6
2.4
2.38
2.26
g/l
1.05
106
485
180
1054
2.50
15.42
3.7
2.7
48.81
66.87
u/l
2.29
170
974
117
566
2.63
14.94
2.6
2.4
11.73
12.75
umol/l
0.76
108
530
115
567
2.55
13.98
3.5
3.5
0.80
0.82
mmol/l
0.93
107
541
266
1920
2.77
13.89
6.3
3.5
75.77
54.18
u/l
1.88
257
1791
232
1615
2.37
12.33
17.9
14.1
1.25
1.25
inr
0.01
202
1340
145
835
2.28
12.12
2.5
2.2
3.14
3.03
mg/l
0.18
125
726
204
1378
2.20
11.20
28.4
12.3
0.00
0.00
e9/l
0.24
181
1130
60
244
2.77
10.48
1.7
1.7
—
—
—
0
0
10
0
+∞
10.47
2.3
0.0
183.87
—
umol/24h
—
10
0
162
1048
2.04
9.42
4.1
3.8
31.20
34.72
u/l
0.74
154
993
73
349
2.39
9.08
4.8
3.3
—
—
—
0
0
111
699
1.87
6.45
2.1
1.8
107692712.64
27116162.72
pmol/l
0.33
91
579
23
72
3.35
6.27
1.1
1.4
—
—
—
0
0
69
373
2.07
6.22
2.8
3.4
9.05
9.55
umol/l
0.07
60
342
58
296
2.16
6.06
2.3
2.7
31.98
35.06
u/l
0.18
51
249
185
1379
1.75
5.97
3.4
2.4
69.14
78.04
nmol/l
3.91
169
1210
26
92
2.98
5.81
2.3
1.5
—
—
—
0
0
138
962
1.73
5.54
3.8
3.4
0.31
0.43
e6/l
0.67
115
710
41
189
2.33
5.45
2.1
3.8
1.84
1.95
mmol/l
0.05
28
146
247
2040
1.77
5.17
5.8
4.9
306.50
277.89
e6/l
—
6
37
177
1337
1.68
5.17
3.5
2.9
164.60
143.71
ug/l
0.50
164
1227
46
230
2.16
5.05
2.7
3.6
5.17
5.11
kpa
0.20
46
225
188
1458
1.65
4.84
3.8
3.0
—
—
estimate
—
0
0
68
407
1.84
4.49
3.8
4.8
224.97
250.33
u/l
1.03
62
384
149
1110
1.61
4.38
4.2
3.5
42.49
117.43
e6/l
0.63
124
863
186
1470
1.59
4.20
2.4
2.2
88.20
97.63
pmol/l
1.90
122
766
14
44
3.28
3.82
1.2
1.3
—
—
—
0
0
261
2274
1.64
3.59
5.3
4.1
14.68
14.97
pmol/l
1.10
242
2028
42
234
1.91
3.45
3.1
3.1
105.31
77.00
ng/l
1.00
37
207
13
42
3.18
3.40
4.1
6.5
7.51
6.74
mmol/l
0.27
13
37
11
28
4.02
3.31
1.5
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
104
2.30
3.24
2.4
2.8
0.31
0.35
iu/ml
0.24
13
56
167
1341
1.48
3.19
4.7
4.1
50.53
36.28
ng/l
0.30
140
1048
118
895
1.49
2.94
4.7
3.6
0.03
0.08
estimate
0.24
60
298
83
588
1.54
2.84
2.2
1.7
1449.49
1218.77
nmol/l
0.88
55
437
50
755
0.60
2.77
3.9
4.3
1.02
1.02
kg/l
0.26
43
504
16
68
2.42
2.60
1.3
6.9
—
147.89
—
0
9
12
44
2.79
2.57
1.3
1.6
—
—
—
0
0
276
2963
0.64
2.57
5.5
6.4
2.35
2.61
mmol/l
4.36
245
2709
76
540
1.52
2.55
3.4
3.3
3.02
2.12
e6/l
0.24
40
275
269
2897
0.66
2.42
5.1
5.4
1.43
1.46
mmol/l
0.46
237
2639
22
112
2.03
2.36
1.2
1.2
—
—
—
0
0
257
2786
0.68
2.29
4.1
4.6
1.37
1.27
mmol/l
1.24
220
2518
128
1032
1.39
2.17
1.9
1.7
20.68
20.59
nmol/l
0.02
112
853
6
14
4.34
2.16
2.0
1.4
48.50
66.47
ug/l
—
6
14
272
2908
0.68
2.09
5.0
5.5
4.27
4.52
mmol/l
3.07
239
2672
9
31
2.95
2.08
1.8
1.2
—
—
—
0
0
13
56
2.37
2.07
3.7
2.2
9.84
8.08
pmol/l
0.26
13
56
310
2922
1.69
2.03
34.0
17.8
27.35
24.87
mg/l
0.64
285
2416
11
44
2.55
2.03
1.5
1.8
90.44
89.60
%
0.31
11
44
13
267
0.47
2.01
4.9
2.7
45.33
61.40
ml/min/173m2
—
6
110
100
786
1.39
1.95
3.6
2.4
—
—
—
0
0
77
580
1.42
1.91
1.9
1.9
—
—
—
0
0
10
42
2.42
1.63
1.5
1.1
13.78
25.89
iu/ml
—
5
9
57
427
1.40
1.47
6.3
9.6
0.38
1.03
mmol/l
0.50
48
361
82
1006
0.76
1.40
4.0
5.0
22.47
21.26
%
0.38
46
518
7
29
2.44
1.40
1.4
1.8
—
—
—
0
0
16
89
1.84
1.39
1.3
1.8
—
—
—
0
0
19
112
1.74
1.38
5.6
3.7
1.62
2.81
ratio
—
10
61
5
17
2.97
1.36
1.0
1.5
—
—
—
0
0
13
69
1.92
1.30
1.2
1.7
—
—
—
0
0
12
62
1.97
1.29
1.3
2.0
—
—
—
0
0
21
131
1.64
1.27
3.5
3.0
—
—
—
0
0
5
19
2.65
1.22
2.6
2.2
—
—
—
0
0
11
57
1.96
1.18
1.5
2.9
—
1327.40
—
0
5
10
50
2.03
1.17
1.3
1.7
—
—
—
0
0
173
1549
1.24
1.16
2.2
2.7
—
—
—
0
0
16
95
1.72
1.16
1.3
1.8
—
—
—
0
0
14
81
1.76
1.10
1.2
1.7
—
—
—
0
0
13
217
0.58
1.10
2.4
2.7
0.82
1.26
%
1.62
13
217
132
1161
1.22
1.02
3.2
3.4
6.44
7.64
mmol/l
3.43
106
959
10
53
1.91
1.02
1.2
1.3
—
—
—
0
0
10
53
1.91
1.02
1.2
1.3
—
—
—
0
0
13
212
0.60
1.02
2.2
2.7
0.79
0.65
%
0.76
13
212
15
92
1.66
0.99
3.3
3.4
5.50
2.33
index
—
8
58
110
1257
0.82
0.98
5.2
5.8
1.87
2.58
ug/l
1.29
98
1128
72
596
1.26
0.96
3.5
3.1
0.84
1.02
e6/l
0.35
39
328
7
37
1.91
0.94
1.1
1.8
—
—
—
0
0
112
976
1.22
0.94
4.5
4.3
0.00
0.01
estimate
0.50
70
337
13
207
0.61
0.94
4.2
3.8
46.48
48.89
%
0.14
13
202
51
417
1.26
0.77
4.6
5.2
34.59
31.79
%
0.98
32
265
11
67
1.66
0.76
1.2
1.7
—
—
—
0
0
78
670
1.21
0.75
1.3
1.3
0.80
1.53
u/ml
1.03
19
180
5
26
1.94
0.71
1.0
1.3
—
—
—
0
0
5
26
1.94
0.71
1.0
1.3
—
—
—
0
0
5
26
1.94
0.71
2.6
3.2
1.00
0.88
index
—
5
26
5
26
1.94
0.71
3.6
3.7
70.20
62.87
u/ml
—
5
26
12
180
0.65
0.70
1.6
1.2
121.42
290.61
u/ml
0.78
12
166
10
61
1.66
0.69
2.8
3.4
14.50
30.00
u/ml
—
10
61
7
44
1.60
0.65
1.6
1.5
—
—
—
0
0
7
44
1.60
0.65
1.6
1.5
—
—
—
0
0
7
44
1.60
0.65
6.1
4.5
—
—
—
0
0
8
129
0.61
0.65
1.1
2.0
227.13
287.08
ug/l
—
8
122
239
2276
1.17
0.63
4.4
4.5
16.20
12.85
mm/h
1.88
219
2093
16
113
1.44
0.62
2.1
1.8
—
—
—
0
0
31
387
0.78
0.62
9.7
7.7
—
—
—
0
0
5
30
1.68
0.61
2.0
1.0
—
—
—
0
0
0
20
0.00
0.60
0.0
1.0
—
—
—
0
0
47
393
1.23
0.60
1.3
1.5
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
165.25
—
0
23
11
160
0.68
0.57
1.1
1.4
—
60.29
—
0
15
178
1669
1.14
0.56
4.5
4.2
0.00
0.00
estimate
-0.00
74
361
13
90
1.46
0.56
1.2
1.7
—
—
—
0
0
6
37
1.63
0.56
3.0
2.4
—
—
—
0
0
280
2713
1.18
0.53
6.3
5.3
1.87
1.98
mu/l
0.75
263
2449
179
1685
1.13
0.52
4.5
4.2
0.00
4.44
estimate
0.50
79
366
7
45
1.57
0.49
1.6
1.5
—
—
—
0
0
7
45
1.57
0.49
1.6
1.5
—
—
—
0
0
292
2845
1.19
0.48
9.7
7.1
41.25
39.98
mmol/mol
1.75
274
2647
7
46
1.53
0.48
1.6
1.5
—
—
—
0
0
7
46
1.53
0.48
1.6
1.5
—
—
—
0
0
78
698
1.15
0.48
1.8
1.8
1.82
1.46
mg/l
0.48
59
566
7
48
1.47
0.47
1.1
1.3
—
163.45
—
0
12
16
120
1.35
0.47
2.3
1.9
—
—
—
0
0
17
130
1.32
0.45
1.1
1.1
—
—
—
0
0
17
130
1.32
0.45
2.4
1.5
0.55
0.35
mg/l
—
8
54
179
1701
1.11
0.41
4.5
4.2
0.00
0.90
estimate
0.51
77
339
0
16
0.00
0.41
0.0
1.1
—
1.06
—
0
9
67
744
0.88
0.41
3.4
3.4
0.72
0.77
ug/l
0.35
49
501
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
8
61
1.32
0.40
1.4
1.2
0.99
0.92
g/l
—
8
61
8
61
1.32
0.40
1.3
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
2.3
—
13.46
—
0
19
124
1323
0.90
0.39
2.1
2.0
1.40
1.33
mmol/l
0.47
93
1084
71
644
1.13
0.37
2.9
4.1
202.49
357.88
ng/l
0.50
62
540
125
1174
1.10
0.35
4.1
4.1
9.01
7.13
mg/mmol
0.16
71
738
49
436
1.14
0.34
1.6
1.8
—
—
—
0
0
36
313
1.17
0.34
1.4
1.7
1.62
1.58
%
0.15
31
266
6
45
1.34
0.34
1.3
1.1
—
—
—
0
0
11
143
0.76
0.32
1.6
1.8
—
—
—
0
0
10
74
1.36
0.32
1.1
1.1
—
13.01
—
0
8
6
47
1.28
0.32
7.0
2.1
9.33
10.47
mmol/l
—
6
47
13
102
1.29
0.30
1.4
1.4
—
—
—
0
0
10
128
0.77
0.27
1.5
1.7
—
—
—
0
0
311
3070
1.15
0.26
29.3
13.3
27.55
25.43
u/l
1.63
306
2973
9
74
1.22
0.25
1.2
1.1
—
6.58
—
0
10
9
75
1.21
0.25
1.0
1.2
—
1.04
—
0
5
24
209
1.16
0.23
1.6
1.6
—
—
—
0
0
12
97
1.25
0.23
1.6
1.2
—
—
—
0
0
45
412
1.11
0.22
1.6
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
9.31
—
0
11
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
24
271
0.88
0.20
1.3
1.4
—
—
—
0
0
47
509
0.91
0.20
1.3
1.3
1.51
12.16
u/ml
2.40
19
189
0
14
0.00
0.20
0.0
1.4
—
13.29
—
0
14
6
49
1.23
0.20
1.2
1.2
—
—
—
0
0
316
3131
1.13
0.19
52.2
27.8
38.34
40.23
%
9.15
310
3098
316
3131
1.13
0.19
51.5
27.2
4.23
4.46
e12/l
11.56
311
3065
316
3132
1.13
0.18
51.8
27.3
126.56
134.94
g/l
16.05
311
3099
133
1284
1.06
0.18
4.8
4.1
0.04
0.01
estimate
0.34
70
301
7
60
1.17
0.18
1.1
1.5
—
163.33
—
0
6
7
60
1.17
0.18
1.7
1.6
—
—
—
0
0
8
70
1.15
0.16
1.4
1.3
—
—
—
0
0
12
138
0.86
0.13
1.7
1.4
—
—
—
0
0
87
838
1.05
0.12
3.4
3.0
371.59
354.46
umol/l
0.76
79
722
11
97
1.14
0.09
1.2
1.2
—
—
—
0
0
288
2901
0.95
0.09
7.7
5.6
6.42
6.06
mmol/l
4.36
271
2633
5
64
0.78
0.08
1.0
1.2
—
—
—
0
0
11
98
1.13
0.07
1.2
1.2
—
—
—
0
0
9
84
1.07
0.07
1.3
1.5
—
—
—
0
0
9
85
1.06
0.07
1.0
1.3
—
2.00
—
0
15
56
543
1.04
0.06
1.3
1.3
13.90
38.95
iu/ml
3.80
20
159
18
192
0.93
0.05
1.5
1.4
—
—
—
0
0
34
354
0.96
0.05
4.2
3.6
1.20
1.95
mmol/l
0.47
25
304
21
199
1.06
0.04
4.5
3.5
23.26
24.46
mmol/l
1.09
21
199
10
92
1.09
0.03
1.6
1.4
—
—
—
0
0
31
302
1.03
0.02
4.3
2.6
0.22
0.22
e6/l
0.00
31
288
32
321
1.00
0.00
1.5
1.5
—
—
—
0
0
10
95
1.05
0.00
1.3
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
7.44
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.18
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1.30
—
0
5
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
-0.00
1.0
1.2
1.57
1.54
g/l
—
6
59
8
84
0.95
-0.00
1.1
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
80.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
-0.00
1.9
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.9
—
36.38
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_CARCISDR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CARCISDR | 4.015 [3.24, 4.98] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.136 |
During the follow-up period (1.1.1998 — 31.12.2019), 304 out of 704 females with E4_CARCISDR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_CARCISDR | 3.911 [3.06, 4.99] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.034 |
During the follow-up period (1.1.1998 — 31.12.2019), 305 out of 623 males with E4_CARCISDR died.
Mortality risk
Mortality risk for people of age
years, who have E4_CARCISDR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.313% | 0.692% |
| 5 | 2.093% | 4.777% |
| 10 | 5.068% | 11.321% |
| 15 | 9.75% | 20.778% |
| 20 | 16.571% | 33.927% |
Relationships between endpoints
↥Index endpoint: E4_CARCISDR – Carcinoid syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data